 |
ABT
$ABT (Abbott Laboratories) $53.92 crossed its 1st Pivot Point Resistance #emppv #stocks
http://empirasign.com/l/6wno.htm
ABT
$ABT (Abbott Laboratories) $53.38 crossed its 1st Pivot Point Support #emppv #stocks
http://empirasign.com/l/jewa.htm
ABT
Looking for support at/near $SPX 1050 added to OAKBX FNARX FEMKX $ABT $MO - $$
ABT
$ABT (Abbott Laboratories) $54.12 crossed its 1st Pivot Point Support #emppv #stocks
http://empirasign.com/l/jkb0.htm
ABT
Abbott $ABT Labs won't lose appetite for acquisitions under Miles White following year of drug, nutrition and device buys. http://tr.im/ML7F
ABT
RT @empirasign_eq: Empirasign Most Popular Tweets for Feb 2 http://empirasign.com/l/2ti.htm $ABT $WFMI $MMC $DUK #metals #stocks #popular #e
ABT
Empirasign Most Popular Tweets for Feb 2 http://empirasign.com/l/2ti.htm $ABT $WFMI $MMC $DUK #metals #stocks #popular #emga
ABT
$ABT (Abbott Laboratories) $54.40 crossed its 3rd Pivot Point Resistance #emppv #stocks
http://empirasign.com/l/il4.htm
ABT
$ABT (Abbott Laboratories) $54.40 has crossed its 50 day moving average: $54.28 #empta #stocks
http://empirasign.com/l/jus.htm
ABT
$ABT (Abbott Laboratories) $54.18 crossed its 2nd Pivot Point Resistance #emppv #stocks
http://empirasign.com/l/w8v.htm
ABT
$ABT (Abbott Laboratories) $53.74 crossed its 1st Pivot Point Resistance #emppv #stocks
http://empirasign.com/l/36a.htm
ABT
$ABT (Abbott Laboratories) $53.11 crossed its 2nd Pivot Point Support #emppv #stocks
http://empirasign.com/l/xrl.htm
ABT
$ABT (Abbott Laboratories) $53.48 crossed its 1st Pivot Point Support #emppv #stocks
http://empirasign.com/l/inu.htm
ABT
A Greek Tragedy? http://cnbc.com/id/35126510 $AAPL $ABT $BA $BMY $CL $MMM $PG #StockPicks #StockMarket - http://tinyurl.com/yfzl6y3
ABT
A Greek Tragedy? http://cnbc.com/id/35126510 $AAPL $ABT $BA $BMY $CL $MMM $PG #StockPicks #StockMarket
Abbott Laboratories - ABT Insiders
No Insiders
We have no insiders for Abbott Laboratories right now.
Know someone who is an insider on Abbott Laboratories?
Let us know.
Abbott Laboratories - ABT information
Abbott Laboratories manufactures and sells health care products worldwide. The company?s Pharmaceutical Products segment offers adult and pediatric pharmaceuticals for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, dyslipidemia, HIV infection, hypothyroidism, advanced prostate cancer, endometriosis and central precocious puberty, anemia caused by uterine fibroids, obesity, epilepsy and bipolar disorder, migraines, and secondary hyperparathyroidism; and provides anesthesia products and anti-infectives. Its Diagnostic Products segment offers immunoassay systems; chemistry systems; assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases, and infectious diseases; instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infections agents; genomic-based tests; hematology systems and reagents; and point-of-care diagnostic systems and tests for blood analysis. The company?s Nutritional Products segment provides various forms of prepared infant formula and follow-on formula, adult and other pediatric nutritional products, nutritional products used in enteral feeding in health care institutions, and bars and nutritional brands. Its Vascular Products segment offers coronary, endovascular, and vessel closure devices, such as drug-eluting coronary stent systems, coronary metallic stents, balloon dilatation products, coronary guidewires, vessel closure devices, and carotid stent systems to treat vascular disease. Abbott serves wholesalers, government agencies, health care facilities, specialty pharmacies, independent retailers, hospitals, clinics, physicians' offices, blood banks, commercial laboratories, alternate-care testing sites, plasma protein therapeutic companies, and third-party distributors. The company was founded in 1888 and is based in Abbott Park, Illinois....
www.abbott.com
73,000 Employees
Founded in 1888
ABBOTT LABORATORIES (ABT:NYSE)
LAST $55.03 USD
CHANGE TODAY +0.23 0.42%
VOLUME 8.2M
As of 8:04 PM 03/10/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of ABBOTT LABORATORIES (ABT)
|
OPEN
$54.81
|
PREVIOUS CLOSE
$54.80
|
|
|
DAY HIGH
$55.55
|
DAY LOW
$54.72
|
|
|
52 WEEK HIGH
01/20/10 - $56.79
|
52 WEEK LOW
05/1/09 - $41.27
|
|
|
MARKET CAP
85.4B
|
AVERAGE VOLUME 10 D
6.1M
|
|
|
EPS TTM
$3.72
|
SHARES OUTSTANDING
1.6B
|
|
|
EX-DATE
04/13/10
|
P/E TTM
14.8x
|
|
|
DIVIDEND
$1.76
|
DIVIDEND YIELD
2.91%
|
|
| K = Thousands M = Millions B = Billions | ||
related news
*Terra Industries, AIG, J. Crew are big movers
AP Digital - 03/10/2010 7:03 PM ET
*Final Glance: Medical Devices companies
AP Digital - 03/10/2010 6:05 PM ET
Abbott gets FDA approval for implantable lens
AP Digital - 03/10/2010 4:17 PM ET
Moody's affirms 'Negative' outlook for Abbott
AP Digital - 03/10/2010 3:59 PM ET
Midday Glance: Medical Devices companies
AP Digital - 03/10/2010 1:20 PM ET
Key developments for ABBOTT LABORATORIES (ABT)
BG Medicine and Abbott to Develop Galectin-3 Test for the I-Stat System
03/8/2010
BG Medicine, Inc. announced that it has entered into an agreement with Abbott Laboratories to extend its current development and commercialization collaboration to include the development of a galectin-3 test for Abbott Point of Care's i-STAT(R) System. Galectin-3 is a novel biomarker that may play a role in detecting the development and progression of heart failure. Under the agreement, Abbott will be responsible for the development of the test in accordance with certain plans and milestones, and BG Medicine and Abbott will collaborate in support of regulatory filings and studies to support the clinical utility of galectin-3 in the management of patients with acute decompensated heart failure.
Abbott Laboratories Amends By-Laws
02/22/2010
On February 19, 2010, the board of directors of Abbott Laboratories amended the first sentence of Article III, Section 2 of the companys by-laws to provide that Abbotts board of directors shall consist of 12 persons, effective as of April 23, 2010. The companys by-laws previously provided that the board of directors consisted of 13 persons.
Alapis, Stada, Abbott And Omnia Reportedly Acquire Galenikas Tender Documents
02/22/2010
Alapis SA, Stada Arzneimittel AG, Abbott Laboratories and Omnia Capital SA have bought tender documents for the privatization of 70% stake in Galenika a.d., B92 television reported. The Serbian Privatization Agency refused to name the companies but confirmed that three pharmaceutical companies and one investment firm were involved. The agency said the names of the companies would be released on March 19, the deadline for them to table letters of intent. "One of the companies gave us a clear position that they will not attend tender if we publish that they bought tender documentation", a source from the agency told B92, which claims the firm was Stada. Alapis said that it is interested in any worthwhile opportunity that may arise in the Serbian market. Galenika is not the only objective in Serbia. We are convinced of the countrys potential, Senior Director Giannis Georgakopoulos said in a statement. To fund potential acquisitions, Alapis plans to utilize part of the 451.1 million it raised through a rights issue.
ABT Competitors
| Company | Last | Change |
| Danone | €44.20 EUR | -0.055 |
| Eli Lilly & Co | $35.34 USD | +0.28 |
| Express Scripts Inc | $98.59 USD | +0.26 |
| Koninklijke Philips Electronics NV | €23.96 EUR | -0.03 |
| Merck & Co Inc | $36.67 USD | -0.37 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | ABT | Industry Range |
| Price/Earnings | 14.9x |
|
| Price/Sales | 2.8x |
|
| Price/Book | 3.7x |
|
| Price/Cash Flow | 14.9x |
|
| TEV/Sales | 1.9x |
|
|
ABT |
||
|
ABT transactions
| Type Date |
Target |
|
Merger/Acquisition
March 9, 2010 |
Facet Biotech Corporation |
|
Merger/Acquisition
December 14, 2009 |
Starlims Technologies Ltd |
|
Merger/Acquisition
December 9, 2009 |
Abbott Laboratories, cGMP Commercial Facility in Edison, NJ |
Abbott Laboratories - ABT news
Abbot to buy Facet Biotech for $450M
2010-03-10 02:38:21
Quote: Abbott Laboratories Inc. will buy Facet Biotech Corp. for about $450 million, the companies said Tuesday.Abbott Park, Ill.-based Abbott (NYSE:ABT) will pay a purchase price of about $722 million, less Facet's projected cash and marketable securities at closing of about $272 million.The $27 per-share price for Redwood City-based Facet (NASDAQ:FACT) is $10.79 higher than the company's closing share price Tuesday of $16.21."The acquisition brings access to biologics in two key therapeu...Read article
Business Highlights
2010-03-10 02:38:20
Quote: It would add $132 billion to the budget deficit over the next year and a half.Eight Republicans voted with Democrats to defeat a GOP filibuster of the measure, setting up a final vote on Wednesday.Abbott paying $450 million for Facet BiotechNEW YORK (AP) -- Abbott Laboratories says it will buy Facet Biotech for about $450 million in cash, expanding the company's access to biotechnology drugs, including a potential treatment for multiple sclerosis.Facet and its partner Biogen Idec plan to move th...Read article
Abbott to Buy Facet Biotech for 67% Premium
2010-03-10 02:38:18
Keywords: Mergers & Acquisitions, Investment Banking, I PO, I.P.O.s, IPOs, Offerings, Private Equity, Hedge Funds, Venture Capital, Legal, The New York Times, Andrew Ross Sorkin, Andrew Sorkin, DealBook, deal maker, Wall street, wall st., Goldman Sachs, Goldman Sa
Quote: Abbott Laboratories announced late Tuesday that it had agreed to buy Facet Biotech for a net price of $450 million in cash, in a move aimed at expanding its drug pipeline, including for treatments for multiple sclerosis.
Under the terms of the deal, Abbott will pay $27 for each Facet share, a 67 percent premium over Facet’s closing price of $16.21 on Tuesday. Facet’s shares jumped slightly above Abbott’s offer in after-hours trading, gaining $10.89, or 67.2 percent, to $27.10, ...Read article
Abbott executives to chair medical device lobby
2010-03-09 07:11:36
Quote: WASHINGTON (AP) -- The medical device industry's chief advocacy group, AdvaMed, said Thursday an Abbott Laboratories executive will serve as its chairman.James Mazzo is President of Abbott Medical Optics, a maker of contacts lenses and vision products which was acquired by Abbott last year. He previously served as the company's chairman and chief executive before its acquisition.Mazzo will serve a two-year term as chairman of AdvaMed's board of directors. He replaces Edwards Lifesciences CEO Mik...Read article
Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy
2010-03-05 06:52:09
Quote: Read article
Abbott executives to chair medical device lobby
2010-03-05 06:52:08
Quote: WASHINGTON (AP) -- The medical device industry's chief advocacy group, AdvaMed, said Thursday an Abbott Laboratories executive will serve as its chairman.James Mazzo is President of Abbott Medical Optics, a maker of contacts lenses and vision products which was acquired by Abbott last year. He previously served as the company's chairman and chief executive before its acquisition.Mazzo will serve a two-year term as chairman of AdvaMed's board of directors. He replaces Edwards Lifesciences CEO Mik...Read article
GE plans new American export--outdoor smoking ban
2010-03-05 06:52:07
Keywords: Industrial conglomerates,Industrial conglomerates (industry),
Quote: Drugmaker Abbott Laboratories
Inc (ABT.N) prohibits employees and visitors from lighting up
at any of its campuses in the United States and Puerto Rico. Some U.S. companies have taken anti-tobacco measures even
further. In 2005, lawn care products maker Scott's Miracle-Gro
Co (SMG.N) said it would no longer hire people in the United
States who smoked and banned its employees from smoking on or
off the job in the U.S. states where it can do so legally. The company today estimates that less than 1...Read article
Senior Analyst Forecasts 3 - 5 Year EPS Growth Estimate Of 10% For Abbot Labs (ABT)
2010-03-04 10:11:31
Quote: Read article
Child seizure study finds oldest drug works best
2010-03-04 10:11:28
Keywords: Health and medicine,Pharmaceuticals (sub-industry),United States of America,Regulation and enforcement,General News,Nature Society and Science,Business activities,Living and lifestyle,United Kingdom,Western Europe,Europe,Company News item,Economic news, E
Quote: (PFE.N) (Ethosuximide), GlaxoSmithKline Plc (GSK.L)
(Lamotrigine) and Abbott Laboratories (ABT.N) (valproic acid). "The older drug gives you better seizure control combined
with fewer attention problems," Dr. Tracy Glauser of Cincinnati
Children's Hospital in Ohio, who led the study, said in a
telephone interview. The study is the first to conclusively compare drug
treatments for childhood absence epilepsy, the most common form
of childhood seizures. The condition usually begins between ages 4 a...Read article
Abbott and Enanta Announce Advancement of Hepatitis C Collaboration
2010-03-03 01:30:19
Quote: Read article
Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis
2010-03-03 01:30:19
Quote: Read article
Abbott, Enanta moving Hepatitis C drug development
2010-03-03 01:30:18
Quote: NEW YORK (AP) -- Abbott Laboratories and partner Enanta Pharmaceuticals on Tuesday said they will move potential hepatitis C treatments into midstage development.The companies said they will evaluate three potential hepatitis C drugs in Phase 2 clinical trials. The drug candidates include ABT-450, which was discovered through the partnership. Also moving into midstage development are ABT-333 and ABT-072, which were both discovered by Abbott.The midstage studies will focus on safety, tolerability...Read article
InPlay: Abbott Labs and Enanta announce advancement of Hepatitis C collaboration
2010-03-03 01:30:18
Keywords: market update, investing education, financial advice, financial planning
Quote: Read article
FDA panel back Bristol-Myers transplant drug
2010-03-02 01:21:31
Quote: Belatacept patients also showed improved kidney function and lower blood pressure, both key predictors of survival.However, the FDA panelists struggled to describe the benefits of the drug, citing higher rates of severe kidney rejection compared with older drugs from Novartis and Abbott Laboratories."I'm not convinced they measured effectiveness adequately," said Dr. Darren Mcguire of the University of Texas Southwestern Medical Center, who voted against approval. "I'm not willing to sacrifice a...Read article
Soleil Securities Analyst Picks 2010 Top Health Services Stocks
2010-03-02 01:21:31
Quote: Read article
UPDATE - U.S. FDA panel backs Bristol transplant drug
2010-03-02 01:21:30
Keywords: Pharmaceuticals - diversified,Pharmaceuticals (sub-industry),United States of America,Washington / US Government News,Regulation and enforcement,Health and medicine,Switzerland,Western Europe,Europe,Healthcare,Pharmaceuticals and biotechnology,General New
Quote: Most panelists noted that belatacept was not quite as
effective as current treatments such as cyclosporine, a type of
calcineurin inhibitor (CNIs) sold as Abbott Laboratories'
(ABT.N) Gengraf and Novartis's (NVS.N) Sandimmune and Neoral. That trade off, though was worth it, said panelist
Frederick Kaskel, because "We need to offer patients options." FDA staff reviewers have cited concerns about possible
serious complications even though data showed better heart
risks and kidney function, citing ...Read article
UPDATE - U.S. FDA panel backs Bristol transplant drug
2010-03-02 01:21:30
Keywords: Pharmaceuticals - diversified,Pharmaceuticals (sub-industry),United States of America,Washington / US Government News,Regulation and enforcement,Health and medicine,Switzerland,Western Europe,Europe,Healthcare,Pharmaceuticals and biotechnology,General New
Quote: Most panelists noted that belatacept was not quite as
effective as current treatments such as cyclosporine, a type of
calcineurin inhibitor (CNIs) sold as Abbott Laboratories'
(ABT.N) Gengraf and Novartis's (NVS.N) Sandimmune and Neoral. That trade off, though was worth it, said panelist
Frederick Kaskel, because "We need to offer patients options." FDA staff reviewers have cited concerns about possible
serious complications even though data showed better heart
risks and kidney function, citing ...Read article
UPDATE - Stents, surgery both prevent strokes-study
2010-03-01 06:25:03
Keywords: Pharmaceuticals (sub-industry),Health and medicine,United States of America,Science; technology,General News,Nature Society and Science,Canada,Hot stocks,Equities,Company News item,Economic news, EC, business/financial pages,
Quote: Several medical device makers sell carotid stents,
including Boston Scientific Corp (BSX.N), Abbott Laboratories
(ABT.N), Johnson & Johnson (JNJ.N), Ev3 Inc (EVVV.O) and C.R.
Bard Inc (BCR.N). Ev3 shares jumped as much as 12.2 percent in morning
trading. The nine-year trial, dubbed the Carotid Revascularization
Endarterectomy vs. Stenting Trial or CREST trial, compared the
safety and effectiveness of surgery versus stenting in 2,502
patients with or without a previous stroke. It showed that ...Read article
Stroke study finds neck stents safe, effective
2010-03-01 06:25:01
Quote: Stents won approval as an alternative for certain patients in 2004; half a dozen companies make the devices now, although Abbott Laboratories stands to benefit most because its stents were in the study.To place them, doctors put a tube in a blood vessel in the groin and push it to the narrowed artery. A parachute-like filter is placed to trap bits of plaque that dislodge and keep them from traveling to the brain. A balloon is inflated to flatten the clog, the stent is placed to hold the artery o...Read article
FDA warns of heart risk with HIV drug combination
2010-02-26 06:23:36
Quote: WASHINGTON (AP) -- The Food and Drug Administration issued a warning Tuesday about potential heart risks when combining two HIV drugs.The agency said preliminary data suggest Roche's Invirase and Abbott Laboratories' Norvir can affect the electrical activity of the heart when used together. Changes to the heart's electrical activity can delay the signals that trigger heart beats.In some cases the problem can cause irregular heart rhythms, leading to lightheadedness, fainting, and even death.The ...Read article